These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10352136)

  • 21. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus type I as a target for gene therapy.
    Gottfredsson M; Bohjanen PR
    Front Biosci; 1997 Dec; 2():d619-34. PubMed ID: 9388165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.
    Lisziewicz J; Sun D; Smythe J; Lusso P; Lori F; Louie A; Markham P; Rossi J; Reitz M; Gallo RC
    Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8000-4. PubMed ID: 8367455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS.
    Ngok FK; Mitsuyasu RT; Macpherson JL; Boyd MP; Symonds GP; Amado RG
    Methods Mol Biol; 2004; 252():581-98. PubMed ID: 15017082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.
    Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A
    RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol.
    Giordano V; Jin DY; Rekosh D; Jeang KT
    Virology; 2000 Feb; 267(2):174-84. PubMed ID: 10662613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression.
    Dropulić B; Lin NH; Martin MA; Jeang KT
    J Virol; 1992 Mar; 66(3):1432-41. PubMed ID: 1738200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
    Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
    Ramezani A; Joshi S
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hairpin ribozyme gene therapy for AIDS.
    Duarte EA; Leavitt MC; Yamada O; Yu M
    Methods Mol Biol; 1997; 74():459-68. PubMed ID: 9204461
    [No Abstract]   [Full Text] [Related]  

  • 35. Gene therapy for infectious diseases: the AIDS model.
    Gilboa E; Smith C
    Trends Genet; 1994 Apr; 10(4):139-44. PubMed ID: 7913251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.
    Dawson PA; Marini JC
    Nucleic Acids Res; 2000 Oct; 28(20):4013-20. PubMed ID: 11024182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.
    Hörster A; Teichmann B; Hormes R; Grimm D; Kleinschmidt J; Sczakiel G
    Gene Ther; 1999 Jul; 6(7):1231-8. PubMed ID: 10455431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of ribozymes in gene therapy approaches to AIDS.
    James W
    Recent Results Cancer Res; 1998; 144():139-46. PubMed ID: 9304715
    [No Abstract]   [Full Text] [Related]  

  • 40. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis.
    Paik SY; Banerjea A; Chen CJ; Ye Z; Harmison GG; Schubert M
    Hum Gene Ther; 1997 Jun; 8(9):1115-24. PubMed ID: 9189769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.